Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice

Haitao Fan(Ningbo University), Behnam Badie(City Of Hope National Medical Center), Edwin R. Manuel(City Of Hope National Medical Center), Ian Zhang(Universidade Federal do Rio de Janeiro), Xuebo Chen(Jilin University), Huaqing Wang(Population Health Research Institute), Leying Zhang(City Of Hope National Medical Center), Don J. Diamond(City of Hope), Anna Da Fonseca(Universidade Federal do Rio de Janeiro), Andrew Raubitschek
Clinical Cancer Research
August 17, 2012
10.1158/1078-0432.ccr-12-1911
Cited by 59

Related Papers

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
|Blood|2012|530
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses
|Nature Biotechnology|2009|378